<DOC>
	<DOCNO>NCT02092363</DOCNO>
	<brief_summary>This open-label Phase 1b dose-escalation study ass safety , tolerability , PK OMP-54F28 combine paclitaxel carboplatin . OMP-54F28 administered IV Days 1 21-day cycle . Paclitaxel ( 175 mg/m2 ) carboplatin ( AUC = 5 mg/mL • min ) administer IV Day 1 cycle . A total 6 cycle paclitaxel carboplatin give . Additional cycle may give per institutional standard care discussion Medical Monitor . Treatment OMP-54F28 continue completion treatment paclitaxel carboplatin . The plan dose level OMP-54F28 5 10 mg/kg .</brief_summary>
	<brief_title>Dose Escalation Study OMP-54F28 Combination With Paclitaxel Carboplatin Patients With Recurrent Platinum-Sensitive Ovarian Cancer</brief_title>
	<detailed_description>Depending safety study , additional low intermediate dose level may evaluate . Depending emerge safety data Phase 1a study 54F28-001 continue dose escalation , additional high dose level OMP-54F28 may evaluate study . Alternative dose schedule OMP-54F28 may explore base emerge nonclinical clinical data safety , PD , PK efficacy . The start dose new dose schedule choose result AUC equivalent high dose level clear previously study dosing schedule . No dose escalation OMP-54F28 allow within dose cohort . Once maximum tolerate dose ( MTD ) maximum administer dose ( MAD ) determine , 10 patient may enrol cohort-expansion phase well characterize safety , tolerability PK OMP-54F28 combine paclitaxel carboplatin . Up approximately 34 patient may enrol study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Signed Informed Consent Form Age ≥18 year Histologically document ovarian , primary peritoneal fallopian tube cancer Recurrent platinumsensitive disease , define disease progression ≥6 month complete minimum 4 cycle platinumcontaining regimen Availability FFPE tumor tissue , either archival obtain study entry fresh biopsy Tumor tissue fine needle aspiration acceptable . ECOG performance status 0 1 All acute treatmentrelated toxicity prior therapy must resolve Grade ≤ 1 prior study entry Adequate hematologic endorgan function Evaluable measurable disease per RECIST v1.1 For woman childbearing potential , agreement use two effective form contraception Nonepithelial ovarian carcinoma , include malignant mixed Mullerian tumor Prior treatment paclitaxel carboplatin recurrent platinumsensitive ovarian cancer Treatment anticancer therapy , include radiotherapy , chemotherapy , biologic therapy , herbal therapy within 3 week 5 halflives ( systemic agent ) , whichever short Known hypersensitivity component study treatment result drug discontinuation Grade ≥ 2 sensory neuropathy Uncontrolled seizure disorder active neurologic disease Untreated brain metastasis Leptomeningeal disease manifestation cancer Active infection require antibiotic Bisphosphonate therapy symptomatic hypercalcemia Known history clinically significant liver disease , include active viral hepatitis cirrhosis Significant intercurrent illness include , limited , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnancy , lactation , breastfeed Known HIV infection Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Concurrent use therapeutic warfarin New York Heart Association Classification III IV Known clinically significant gastrointestinal disease include , limited , inflammatory bowel disease Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior first dose study treatment anticipation need major surgical procedure course study Osteoporosis base Tscore &lt; 2.5 leave right total hip , leave right femoral neck lumbar spine ( L1L4 ) determine DEXA scan Bone metastases one following : Prior history pathologic fracture Lytic lesion require impend orthopedic intervention Lack treatment bisphosphonate denosumab Treatment thiazolidinedione PPAR gamma inhibitor ; e.g . Actos® ( pioglitazone ) Avandia® ( rosiglitzone ) Active treatment oral IV glucocortocoid ≥4 week daily dose equivalent great 7.5 mg oral prednisone Fasting βCTX &gt; 1000 pg/mL Metabolic bone disease , hyperparathyroidism , Paget 's disease osteomalacia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Platinum-Sensitive Ovarian Cancer</keyword>
</DOC>